How many drugs treat Fabry's disease?

Drug Landscape tracks 6 marketed treatments for Fabry's disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/fabry-s-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Fabry's disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fabry's disease (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Fabry's disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Elfabrio	PEGUNIGALSIDASE ALFA	Chiesi Farmaceutici S.P.A	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]		2023-01-01
Galafold	MIGALASTAT	Amicus Therap Us		Alpha-galactosidase A	2018-01-01
Fabrazyme	AGALSIDASE BETA	Sanofi	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]		2003-01-01
Replagal	Replagal	National Institute of Neurological Disorders and Stroke (NINDS)
ELFABRIO	PEGUNIGALSIDASE ALFA-IWXJ	CHIESI FARMACEUTICI SPA	Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC]
agalsidase	agalsidase	Amicus Therapeutics

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 1 drug in Fabry's disease
Amicus Therap Us · 1 drug in Fabry's disease
Amicus Therapeutics · 1 drug in Fabry's disease
CHIESI FARMACEUTICI SPA · 1 drug in Fabry's disease
Chiesi Farmaceutici S.P.A · 1 drug in Fabry's disease
National Institute of Neurological Disorders and Stroke (NINDS) · 1 drug in Fabry's disease
Sanofi · 1 drug in Fabry's disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Fabry's disease:

Cite this brief

Drug Landscape (2026). Fabry's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/fabry-s-disease. Accessed 2026-06-10.

Fabry's disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing